Wegovy-maker Novo Nordisk to spend $4.1 billion to boost US manufacturing
By Isabelle Yr Carlsson and Maggie Fick COPENHAGEN/LONDON (Reuters) – Obesity drug-maker Novo Nordisk will spend $4.1 billion to build a U.S. facility to fill injection pens for its hugely popular weight-loss treatment Wegovy and diabetes drug Ozempic, it said on Monday. Construction of the plant at Novo’s existing main U.S. manufacturing site in Clayton,…